esearchers at the University of Barcelona’s Institute of Neurosciences (UBneuro) have uncovered new molecular mechanisms linked to cognitive decline in Alzheimer’s disease. The study, published in Alzheimer’s & Dementia, highlights the critical role of the RTP801 protein in astrocytes—brain cells involved in neuroinflammation and synaptic regulation. This discovery opens new avenues for potential therapeutic targets to combat the disease.
The study, led by Almudena Chicote and Professor Cristina Malagelada, explored the effects of RTP801 protein in astrocytes using animal models. The team found that reducing RTP801 levels in these cells decreased brain hyperconnectivity and partially restored GABA production, a neurotransmitter essential for brain function. These findings suggest that targeting RTP801 could help reverse some of the neural damage seen in Alzheimer’s patients.
Previously, RTP801 was known for its role in neuroinflammation and neuronal dysfunction, but its specific impact on astrocytes was unclear. The researchers used gene therapy techniques to silence RTP801 expression, observing improvements in spatial memory and brain connectivity.
“Astrocytes, once thought to be passive, actively regulate neurodegenerative processes,” said Professor Malagelada. “Silencing RTP801 could restore brain function by improving GABA levels and reducing hyperconnectivity,” added Chicote.
This study provides groundbreaking insights into the role of RTP801 in Alzheimer’s progression, offering hope for future therapies. The team plans further research to validate these findings and explore RTP801 silencing as a potential treatment strategy.
Add comment